novo nordisk denmark - Search News

Novo Nordisk to cap insulin prices in Minnesota settlement

Minnesota AG announces Novo Nordisk settlement capping monthly insulin payments at $35

Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers following its 2018 lawsuit over unaffordable prices that led several diabetics to ration their medications with fatal consequences.

MinnPost · 3d

AG Ellison settles with Novo Nordisk to cap out-of-pocket payments for insulin at $35 a month

Minnesota A.G. Keith Ellison says his office settled with Novo Nordisk to cap monthly out-of-pocket payments for insulin at $35 a month.

Reuters on MSN · 3d

Novo Nordisk to cap insulin prices in Minnesota settlement; joins Lilly, Sanofi

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest insulin makers of charging astronomically high prices for the diabetes drug.

KARE-TV Minneapolis-St. Paul o… · 3d

Novo Norodisk caps insulin prices at $35 for Minnesotans

If you rely on insulin, you will be able to buy Novo Nordisk's products for $35 per month due to a settlement announced Monday.

KIMT · 3d

All Minnesotans can now get insulin for just $35 a month

All Minnesotans, whether they have insurance or not, will be able to buy insulin products for $35 a month for the next five years. State Attorney General Keith Ellison says that’s the result of a settlement announced Monday with Novo Nordisk.

Novo Nordisk’s Ozempic Gets FDA Approval

Washington Examiner on MSN · 13d

Novo Nordisk stock prices drop after Biden lists Ozempic for price negotiations

Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs for mandatory price negotiations.

Wall Street Journal · 2d

Novo Nordisk’s Ozempic Gets FDA Approval as Kidney-Disease Treatment

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type 2 diabetes and chronic kidney disease, Novo Nordisk said.

U.S. News & World Report · 2d

US FDA Approves Novo Nordisk's Ozempic to Cut Risk of Diabetic Kidney Disease Progression

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease (CKD),

12h

Novo Nordisk Foundation granted DKK 10 billion (€1.35 billion) to benefit people and the planet in milestone year

In 2024, on its 100th anniversary, the Novo Nordisk Foundation reached a new milestone, awarding close to DKK 10.1 billion (€1.35 billion) to support nearly 1,800 new projects aimed at improving ...

33mon MSN

Jim Cramer on Novo Nordisk A/S (NVO): ‘They Don’t Have The Production Capability’

We recently compiled a list of the Jim Cramer Shed Light on These 9 Stocks. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other stocks Jim Cramer ...

10d

LVMH dethrones Novo Nordisk as Europe’s most valuable company as Bernard Arnault adds $12 billion to net worth in 2025

Novo Nordisk has faced a massive selloff in recent months amid disappointing drug trials and U.S. pressure to cut its prices.

6don MSN

Novo Nordisk stock pops on phase I data for new weight-loss drug amycretin

Amycretin could give Novo a buzzy product in a newly competitive obesity market. It works similarly to existing GLP-1 ...

J.P. Morgan Reaffirms Their Buy Rating on Novo Nordisk (0QIU)

J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...

PharmiWeb3d

Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity

Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly subcutaneous administration.

Decoding Novo Nordisk's Options Activity: What's the Big Picture?

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Novo Nordisk A/S - share repurchase programme

On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results